Drug Trial Radar · NCT06963411
Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
May 9, 2025
Primary completion
Jul 18, 2025
Study completion Jul 18, 2025
Sponsor
- Lead sponsor
- Kokua Pharma Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of several KP001 dose regimens to identify a treatment regimen with a PK profile that safely meets or exceeds the PK profile of existing injected epinephrine products. The main questions it aims to answer are: * To evaluate any carryover effect with a 7-day washout of different dose regimens of KP001 in healthy adult volunteers. * To evaluate the safety, tolerability and PK of different dose regimens of KP001 in healthy adult volunteers. * To explore the safety, tolerability and PK of one KP001 dose regimen without inhalation (breath holding). Participants will: * Be admitted to clinical research unit (Day -1) and receive treatment the following day (Day 1) and then will be discharged * Visit the clinic on Days 2 \& 3 post dose for required assessments * Visit the clinic 6 days post their last dose for dosing and repeated until 5 dosing visits have been completed * Visit the clinic for a safety follow-up visit approximately 1 week from last dose administered
Conditions
- Acute Allergic Reaction
- Anaphylaxis
Interventions
KP001Drug
Epinephrine Inhalation Aerosol (0.125 mg per inhalation)
PlaceboDrug
Matched Placebo control (KP001 vehicle only)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The maximal observed plasma concentration (Cmax)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
- Area under the concentration-time curve from time zero to last measurable concentration (AUC0-t)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
- Area under the concentration-time curve from time zero to infinity (AUC0-inf)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
- Time when the maximal plasma concentration is observed (Tmax)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
- Rate at which drug is removed from the body (Kel)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
- Half-life of drug (T1/2)Time frame: 1 hour pre-dose to 6 hours post-dose on Day 1, 8, 15, 22 and 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos HealthClinique Inc.
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.